Retatrutide cuts weight 18.8% at 80 weeks in TRIUMPH-2 diabetes trial
Lilly's triple agonist lowered HbA1c by up to 1.50 points versus 0.45 on placebo, with more nausea and diarrhea reported.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 12 09:45 ETSource: SciTechDaily
The wire
- 01The completed phase 3 TRIUMPH-2 trial in 1,152 adults with obesity and type 2 diabetes found mean weight loss of 11.9%, 16.8% and 18.8% at 4, 9 and 12 mg versus 5.1% on placebo.
- 02Weight reduction has historically been harder to achieve in patients with type 2 diabetes; 47% on 12 mg lost at least 20% of body weight and 31% lost at least 25%, versus 6% and 3% on placebo.
- 03Eli Lilly sponsored the study, published in The Lancet; gastrointestinal adverse events including nausea and diarrhea were more frequent than with placebo, and retatrutide remains investigational.
From the source
Read at scitechdaily.comBeyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial
Retatrutide could help tackle obesity and type 2 diabetes together, with an 80-week trial showing substantial weight loss and better blood sugar control alongside more nausea and diarrhea.
